HRP20220720T1 - Analozi egf(a) s masnim kiselinama kao supstituentima - Google Patents

Analozi egf(a) s masnim kiselinama kao supstituentima Download PDF

Info

Publication number: HRP20220720T1
Authority: HR; Croatia
Prior art keywords: egf; gglu; hooc; 301leu; 2xado
Prior art date: 2016-01-13

Application number

HRP20220720TT

Other languages

English (en)

Croatian (hr)

Inventor

Jianhe Chen

Jesper F. Lau

János Tibor Kodra

Birgit Wieczorek

Lars Linderoth

Henning THØGERSEN

Salka Elbøl RASMUSSEN

Patrick William Garibay

Original Assignee

Novo Nordisk A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-13

Filing date

2017-01-13

Publication date

2022-09-30

2017-01-13 Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S

2022-09-30 Publication of HRP20220720T1 publication Critical patent/HRP20220720T1/hr

Links

125000005313 fatty acid group Chemical group 0.000 title claims 2
108090000765 processed proteins & peptides Proteins 0.000 claims 35
125000003275 alpha amino acid group Chemical group 0.000 claims 16
238000006467 substitution reaction Methods 0.000 claims 16
239000000126 substance Substances 0.000 claims 10
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 8
150000001875 compounds Chemical class 0.000 claims 6
125000001424 substituent group Chemical group 0.000 claims 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 4
150000001413 amino acids Chemical class 0.000 claims 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
238000002965 ELISA Methods 0.000 claims 3
BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 claims 2
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
-1 methylsulfonylcarbamoylamino residue Chemical group 0.000 claims 2
229910052757 nitrogen Inorganic materials 0.000 claims 2
FUOSTELFLYZQCW-UHFFFAOYSA-N 1,2-oxazol-3-one Chemical group OC=1C=CON=1 FUOSTELFLYZQCW-UHFFFAOYSA-N 0.000 claims 1
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 claims 1
PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 claims 1
IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 claims 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 claims 1
125000000539 amino acid group Chemical group 0.000 claims 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
229940125877 compound 31 Drugs 0.000 claims 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
125000003831 tetrazolyl group Chemical group 0.000 claims 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Zoology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

HRP20220720TT 2016-01-13 2017-01-13 Analozi egf(a) s masnim kiselinama kao supstituentima HRP20220720T1 (hr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
CN2016070791		2016-01-13
CN2016076580		2016-03-17
EP16195965		2016-10-27
EP17701078.2A EP3402811B1 (en)	2016-01-13	2017-01-13	Egf(a) analogues with fatty acid substituents
PCT/EP2017/050668 WO2017121850A1 (en)	2016-01-13	2017-01-13	Egf(a) analogues with fatty acid substituents

Publications (1)

Publication Number	Publication Date
HRP20220720T1 true HRP20220720T1 (hr)	2022-09-30

Family

ID=57868232

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP20220720TT HRP20220720T1 (hr)	2016-01-13	2017-01-13	Analozi egf(a) s masnim kiselinama kao supstituentima

Country Status (26)

Country	Link
US (2)	US10822385B2 (2)
EP (1)	EP3402811B1 (2)
JP (2)	JP6797926B2 (2)
KR (1)	KR102417487B1 (2)
CN (1)	CN108473550B (2)
AU (1)	AU2017207862B2 (2)
BR (1)	BR112018013820A2 (2)
CA (1)	CA3010756A1 (2)
CL (1)	CL2018001868A1 (2)
CO (1)	CO2018007440A2 (2)
DK (1)	DK3402811T3 (2)
ES (1)	ES2916998T3 (2)
HR (1)	HRP20220720T1 (2)
HU (1)	HUE058647T2 (2)
IL (1)	IL260043A (2)
LT (1)	LT3402811T (2)
MX (1)	MX2018008681A (2)
MY (1)	MY195199A (2)
PE (1)	PE20181376A1 (2)
PH (1)	PH12018501502A1 (2)
PL (1)	PL3402811T3 (2)
RS (1)	RS63298B1 (2)
RU (1)	RU2747877C2 (2)
SA (1)	SA518391996B1 (2)
SI (1)	SI3402811T1 (2)
WO (1)	WO2017121850A1 (2)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI3402811T1 (sl)	2016-01-13	2022-06-30	Novo Nordisk A/S	Analogi EGF(A) z maščobnokislinskimi substituenti
SI3402782T1 (sl)	2016-01-13	2020-11-30	Grunenthal Gmbh	8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati
CA3011176C (en)	2016-01-13	2023-09-19	Grunenthal Gmbh	3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
CA3011180A1 (en)	2016-01-13	2017-07-20	Grunenthal Gmbh	3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
SI3402784T1 (sl)	2016-01-13	2020-07-31	Gruenenthal Gmbh	Derivati 3-((hetero)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana
MA49617A (fr) *	2017-07-19	2020-05-27	Novo Nordisk As	Analogues d'egf(a), préparation, formulations et utilisations associées
CA3068956A1 (en)	2017-07-19	2019-01-24	Novo Nordisk A/S	Bifunctional compounds
US11358994B2 (en) *	2017-07-27	2022-06-14	Saint Louis University	Fatty acid modified human epidermal growth factor
IL279363B2 (en)	2018-06-21	2025-12-01	Merck Sharp & Dohme	Pcsk9 antagonist compounds
WO2020070276A1 (en)	2018-10-05	2020-04-09	Novo Nordisk A/S	Bifunctional compounds comprising insulin peptides and egf(a) peptides
CA3131997A1 (en)	2019-03-22	2020-10-01	3M Innovative Properties Company	Fall-protection system with monitoring system
CN110357969B (zh) *	2019-05-27	2022-03-08	北京志道生物科技有限公司	一种GLP1-EGFa异源二聚体蛋白、功能及方法
AU2020326265A1 (en)	2019-08-07	2022-02-03	Novo Nordisk A/S	Solid compositions comprising an EGF(A) derivative and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN114641275A (zh)	2019-11-07	2022-06-17	诺和诺德股份有限公司	包含pcsk9抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
EP4076492A4 (en)	2019-12-20	2024-01-17	Merck Sharp & Dohme LLC	PCSK9 ANTAGONIST COMPOUNDS
JP2024527488A (ja)	2021-07-02	2024-07-25	スリーエムイノベイティブプロパティズカンパニー	落下防止安全装置と連動される空中リフト
WO2023012263A1 (en)	2021-08-04	2023-02-09	Novo Nordisk A/S	Solid oral peptide formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007022123A2 (en)	2005-08-11	2007-02-22	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
JP2009510999A (ja)	2005-07-29	2009-03-19	エーエムプロテインコーポレイション	キメラ治療剤
JP5721432B2 (ja)	2007-08-15	2015-05-20	ノボ・ノルデイスク・エー／エス	アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
MX2010011499A (es) *	2008-04-23	2010-11-12	Amgen Inc	Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos.
WO2009143633A1 (en)	2008-05-30	2009-12-03	Institut De Recherches Cliniques De Montreal	Pcsk9 inhibitors and methods of use thereof
TWI516501B (zh) *	2008-09-12	2016-01-11	禮納特神經系統科學公司	Ｐｃｓｋ９拮抗劑類
CN101993485B (zh)	2009-08-20	2013-04-17	重庆富进生物医药有限公司	促胰岛素分泌肽类似物同源二聚体及其用途
CN103052900A (zh)	2010-08-02	2013-04-17	日本电气株式会社	偏振器和发光装置
CN102153652A (zh)	2010-12-10	2011-08-17	浙江大学	一种融合蛋白的表达方法及用途
JP2014510516A (ja)	2011-02-15	2014-05-01	ノヴォノルディスクアー／エス	長時間作用性ｉｌ−１受容体アンタゴニスト
WO2012177741A1 (en) *	2011-06-20	2012-12-27	Genentech, Inc.	Pcsk9-binding polypeptides and methods of use
AU2012311484B2 (en) *	2011-09-23	2017-04-13	Novo Nordisk A/S	Novel glucagon analogues
UY34347A (es)	2011-09-26	2013-04-30	Novartis Ag	Proteínas de función dual para tratar trastornos metabólicos
US20140357838A1 (en) *	2011-12-21	2014-12-04	Novo Nordisk A/S	N-Terminally Modified Insulin Derivatives
EP2851429B1 (en)	2012-05-18	2019-07-24	Adda Biotech Inc.	Protein and protein conjugate for diabetes treatment, and applications thereof
TW201420606A (zh)	2012-08-22	2014-06-01	Lilly Co Eli	同源二聚體蛋白
JP2015533483A (ja)	2012-09-07	2015-11-26	サノフイ	メタボリックシンドロームを治療するための融合タンパク質
EP2986313B1 (en) *	2013-04-18	2019-06-12	Novo Nordisk A/S	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP3052521A1 (en)	2013-10-03	2016-08-10	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
CA2935285A1 (en)	2014-02-21	2015-08-27	Medimmune, Llc	Anti-pcsk9-glp-1 fusions and methods for use
US10570184B2 (en) *	2014-06-04	2020-02-25	Novo Nordisk A/S	GLP-1/glucagon receptor co-agonists for medical use
CN104558198A (zh)	2014-07-25	2015-04-29	成都贝爱特生物科技有限公司	GLP-1类似物和amylin类似物的融合蛋白制备及其用途
US20180207223A1 (en) *	2015-03-19	2018-07-26	Institut De Cardiologie De Montreal	Pcsk9 inhibitory polypolypeptides and methods of use
CN105367884A (zh)	2015-11-02	2016-03-02	陈薇	一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
SI3402811T1 (sl)	2016-01-13	2022-06-30	Novo Nordisk A/S	Analogi EGF(A) z maščobnokislinskimi substituenti
CA3068956A1 (en)	2017-07-19	2019-01-24	Novo Nordisk A/S	Bifunctional compounds
MA49617A (fr)	2017-07-19	2020-05-27	Novo Nordisk As	Analogues d'egf(a), préparation, formulations et utilisations associées

2017
- 2017-01-13 SI SI201731149T patent/SI3402811T1/sl unknown
- 2017-01-13 US US16/069,932 patent/US10822385B2/en active Active
- 2017-01-13 RS RS20220538A patent/RS63298B1/sr unknown
- 2017-01-13 PE PE2018001257A patent/PE20181376A1/es unknown
- 2017-01-13 CA CA3010756A patent/CA3010756A1/en not_active Withdrawn
- 2017-01-13 PL PL17701078T patent/PL3402811T3/pl unknown
- 2017-01-13 LT LTEPPCT/EP2017/050668T patent/LT3402811T/lt unknown
- 2017-01-13 BR BR112018013820-7A patent/BR112018013820A2/pt not_active Application Discontinuation
- 2017-01-13 JP JP2018536444A patent/JP6797926B2/ja active Active
- 2017-01-13 DK DK17701078.2T patent/DK3402811T3/da active
- 2017-01-13 RU RU2018127882A patent/RU2747877C2/ru active
- 2017-01-13 MY MYPI2018702319A patent/MY195199A/en unknown
- 2017-01-13 HU HUE17701078A patent/HUE058647T2/hu unknown
- 2017-01-13 WO PCT/EP2017/050668 patent/WO2017121850A1/en not_active Ceased
- 2017-01-13 ES ES17701078T patent/ES2916998T3/es active Active
- 2017-01-13 MX MX2018008681A patent/MX2018008681A/es unknown
- 2017-01-13 KR KR1020187022105A patent/KR102417487B1/ko not_active Expired - Fee Related
- 2017-01-13 HR HRP20220720TT patent/HRP20220720T1/hr unknown
- 2017-01-13 EP EP17701078.2A patent/EP3402811B1/en active Active
- 2017-01-13 CN CN201780006783.6A patent/CN108473550B/zh active Active
- 2017-01-13 AU AU2017207862A patent/AU2017207862B2/en not_active Ceased
2018
- 2018-06-14 IL IL260043A patent/IL260043A/en unknown
- 2018-07-09 CL CL2018001868A patent/CL2018001868A1/es unknown
- 2018-07-10 SA SA518391996A patent/SA518391996B1/ar unknown
- 2018-07-12 PH PH12018501502A patent/PH12018501502A1/en unknown
- 2018-07-16 CO CONC2018/0007440A patent/CO2018007440A2/es unknown
2020
- 2020-09-17 US US17/024,264 patent/US20200407409A1/en not_active Abandoned
- 2020-11-17 JP JP2020190846A patent/JP2021035989A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CN108473550A (zh)	2018-08-31
AU2017207862A1 (en)	2018-07-05
DK3402811T3 (da)	2022-06-13
US20200407409A1 (en)	2020-12-31
JP6797926B2 (ja)	2020-12-09
PE20181376A1 (es)	2018-09-05
WO2017121850A1 (en)	2017-07-20
PL3402811T3 (pl)	2022-07-11
EP3402811A1 (en)	2018-11-21
JP2019505521A (ja)	2019-02-28
EP3402811B1 (en)	2022-03-30
KR20180100177A (ko)	2018-09-07
RS63298B1 (sr)	2022-07-29
CN108473550B (zh)	2022-11-22
PH12018501502A1 (en)	2019-03-25
US10822385B2 (en)	2020-11-03
US20190016768A1 (en)	2019-01-17
MY195199A (en)	2023-01-11
KR102417487B1 (ko)	2022-07-06
CO2018007440A2 (es)	2018-09-28
RU2018127882A3 (2)	2020-06-19
IL260043A (en)	2018-07-31
RU2018127882A (ru)	2020-02-13
MX2018008681A (es)	2018-09-17
SI3402811T1 (sl)	2022-06-30
SA518391996B1 (ar)	2021-07-14
LT3402811T (lt)	2022-06-10
ES2916998T3 (es)	2022-07-06
HUE058647T2 (hu)	2022-09-28
CA3010756A1 (en)	2017-07-20
BR112018013820A2 (pt)	2018-12-11
RU2747877C2 (ru)	2021-05-17
CL2018001868A1 (es)	2018-08-31
AU2017207862B2 (en)	2020-12-17
JP2021035989A (ja)	2021-03-04

Publication	Publication Date	Title
HRP20220720T1 (hr)	2022-09-30	Analozi egf(a) s masnim kiselinama kao supstituentima
Ikai et al.	1991	Structure of aureobasidin A
Samuelsson	1973	Mistletoe toxins
RU2017125050A (ru)	2019-01-25	Производные fgf21 и их применения
CN105143245B (zh)	2021-02-05	防垢材料
US10647742B2 (en)	2020-05-12	Method for synthesizing etelcalcetide
HRP20221054T1 (hr)	2022-11-11	Novi analozi glp-1
DK2049562T3 (da)	2013-04-15	Peptider med farmakologisk virkning til behandling af lidelser, der er forbundet med forandret cellemigration, såsom cancer
JP2016516734A5 (2)	2017-03-30
SE454699B (sv)	1988-05-24	Peptider och lekemedel innehallande desamma
AU2009292741B2 (en)	2012-03-22	Dendrimeric compounds comprising amino acids, hyperbranched core compound, process for preparation of dendrimeric compounds comprising amino acids and hyperbranched core compound, and use thereof
JPH03504496A (ja)	1991-10-03	水素結合の共有結合置換により安定化されたポリペプチド
JP2015502971A5 (2)	2016-02-18
MY147920A (en)	2013-02-15	Antibacterial and antiviral peptides from actinomadura namibiensis
Dahiya	2007	Synthetic and pharmacological studies on longicalycinin A
Schierholt et al.	2011	Bi-and trivalent glycopeptide mannopyranosides as inhibitors of type 1 fimbriae-mediated bacterial adhesion: variation of valency, aglycon and scaffolding
SI3191504T1 (en)	2018-04-30	Ezrine-derived peptides and their pharmaceutical compositions
US8785399B2 (en)	2014-07-22	Antibacterial peptides
Nair et al.	2014	Formation of a pseudo-β-hairpin motif utilizing the Ant–Pro reverse turn: consequences of stereochemical reordering
DK1629002T3 (da)	2009-04-14	Fremgangsmåde til syntetisering af konformationalt hæmmede peptider, peptidometika og anvendelse deraf som syntetiske vacciner
MX2024007182A (es)	2024-06-26	Polipeptidos de penetracion celular (cpp) y su uso en terapia humana.
FI3894426T3 (fi)	2023-01-13	Lineaariset liuosfaasireitit wnt-heksapeptidejä varten
GR3002316T3 (en)	1992-12-30	Peptide derivatives of cck8, their manufacture and pharmaceutical compositions thereof
Hahn et al.	2007	Pragmatic studies on protein-resistant self-assembled monolayers
FR2818647B1 (fr)	2006-09-29	Glycopeptides immunogenes, criblage, preparation et applications